We identified patients who received recombinant factor VIIa (rFVIIa), factor VIII inhibitor bypass activity (FEIBA), factor VIII or factor IX or had a diagnosis code for coagulation defects (ICD-9 286.xx). Use of antihemophilic drugs was identified through either pharmacy dispensing or provider ...